Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An instance of retinal degeneration that is caused by an inherited modification of the individual's genome.
No HPO annotations are available for this condition.
Age of onset: middle age, infancy, childhood, adulthood, at birth.
The clinical manifestations of aceruloplasminemia are retinal degeneration, diabetes mellitus (DM), and neurologic signs/symptoms . Individuals with aceruloplasminemia often present with iron-restricted microcytic anemia prior to onset of DM or neurologic signs/symptoms. Phenotypic expression varies even within families. A summary of clinical manifestations and age of onset in 71 Japanese individuals is shown in . The manifestations (in order of frequency) are anemia, retinal degeneration, diabetes mellitus, and neurologic signs/symptoms. The neurologic signs/symptoms correspond to regions of brain iron accumulation and include ataxia, involuntary movement, parkinsonism, and cognitive dysfunction .
Aceruloplasminemia is characterized by iron accumulation in the brain and viscera.
Aceruloplasminemia should be suspected in individuals with characteristic MRI findings, more than one of the following clinical findings, and typical results on laboratory testing. MRI. Abnormal low intensities in the liver as well as the striatum, thalamus, and dentate nucleus of the brain on T1- and T2-weighted images are consistent with iron deposition and support a diagnosis of aceruloplasminemia .
Clinical findings
1 FDA-approved treatment is available for inherited retinal dystrophy, including voretigene neparvovec-rzyl (Luxturna, approved 2017). An additional 2 compounds hold orphan drug designation.
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
Marked accumulation of iron in parenchymal tissues including the liver, pancreas, heart, and thyroid can result in diabetes mellitus, cardiac failure, and hypothyroidism.
All affected individuals should have an annual glucose tolerance test starting at age 15 years to evaluate for the onset of diabetes mellitus.
Cardiac evaluation should be performed early in the course of the disease and repeated every year.
10 clinical trials registered, 4 recruiting. Interventions under study include gene therapy, drug therapy, biologic therapy, and medical devices. Pipeline includes 3 PHASE3, 3 PHASE1, 2 EARLY_PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05976139](https://clinicaltrials.gov/study/NCT05976139) |
Data assembled from 6 of 12 sources · Last updated Oct 3, 2026, 8:10 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Table 2.
Clinical Manifestations / Age at Onset in 71 Individuals with Aceruloplasminemia
Source: GeneReviews — "Aceruloplasminemia"
Table 4.
Disorders to Consider in the Differential Diagnosis of Aceruloplasminemia
Disorder | Gene(s) | MOI | Clinical Features
Overlapping | Distinguishing (in aceruloplasminemia)
NBIA with later onset1
Atypical pantothenate kinase-associated neurodegeneration (PKAN) | PANK2 | AR | Radiographic evidence of focal iron accumulation in brain, usually basal ganglia | • Iron accumulation in several visceral organs as well as brain
Development of diabetes retinopathy
| FTL | AD
Copper metabolic disorder
Wilson disease2,3 | ATP7B | AR | Ceruloplasmin deficiency | • Radiographic evidence of iron accumulation in basal ganglia, especially thalamus
Iron accumulation in several visceral organs as well as brain
Iron metabolic disorder
Source: GeneReviews — "Aceruloplasminemia"
Biomarker and diagnostic research for inherited retinal dystrophy has been reported in the published literature.
Luxturna |
voretigene neparvovec-rzyl |
— |
2017 |
Available |
The following drugs have received orphan drug designation from the FDA for inherited retinal dystrophy. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor | Designated | Exclusivity End | Designation Status |
|---|---|---|---|---|---|
2-(4-(((4-methoxyphenyl)thio)methyl)-1H-1,2,3-triazol-1-yl)-N,N-dimethylethan-1-aminium hydrochloride | 2-(4-(((4-methoxyphenyl)thio)methyl)-1H-1,2,3-triazol-1-yl)-N,N-dimethylethan-1-aminium hydrochloride | Miramoon Pharma SL | 2024 | — | Designated |
adeno-associated virus serotype 8 expressing Cas9 gene and single guide RNA targeting R135W mutation in Rhodopsin gene | adeno-associated virus serotype 8 expressing Cas9 gene and single guide RNA targeting R135W mutation in Rhodopsin gene | Chigenovo Co., Ltd. | 2022 | — | Designated |
To establish the extent of disease and needs in an individual diagnosed with aceruloplasminemia, the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended:
Iron deposition. Serum ferritin concentration; brain and abdomen MRI findings
Neurologic findings. Brain MRI
Diabetes mellitus. Glucose tolerance test; blood concentrations of insulin and HbA1c
Retinal degeneration. Examination of the optic fundi and fluorescein angiography
Anemia. Complete blood count
Other. Consultation with a clinical geneticist and/or genetic counselor
Note: Individual case reports indicate the effectiveness of treatment in individuals with aceruloplasminemia; however, no large series of symptomatic persons treated with iron chelators and zinc is available and there is no universally accepted treatment regimen. A systematic review/analysis of studies designed to evaluate the clinical effectiveness of desferrioxamine, deferiprone, deferasirox, and zinc as monotherapy for the initial treatment of various clinical presentations of aceruloplasminemia is needed. Desferrioxamine. Treatment with iron chelating agents (i.e., desferrioxamine) can be considered for symptomatic individuals whose blood hemoglobin concentration is higher than 9 g/dL.
Source: GeneReviews — "Aceruloplasminemia"
Iron supplements. Individuals with aceruloplasminemia erroneously diagnosed as having iron deficiency anemia and treated with iron supplements had accelerated iron accumulation.
Source: GeneReviews — "Aceruloplasminemia"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "Aceruloplasminemia"
10 trials found
Evaluation of thyroid and liver function and complete blood count are indicated annually starting at the time of diagnosis.
Source: GeneReviews — "Aceruloplasminemia"
Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies |
NA |
Fondazione G.B. Bietti, IRCCS |
RECRUITING |
[NCT05626920](https://clinicaltrials.gov/study/NCT05626920) | Disulfiram for Treatment of Retinal Degeneration | PHASE1 | University of Washington | RECRUITING |
[NCT07063030](https://clinicaltrials.gov/study/NCT07063030) | A Study of LX107 Gene Therapy in AIPL1-IRD Patients | EARLY_PHASE1 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | RECRUITING |
[NCT07656753](https://clinicaltrials.gov/study/NCT07656753) | Safety and Efficacy Study of PUMCH-E111 Injection in Subjects With RLBP1 Related Inherited Retinal Dystrophy | EARLY_PHASE1 | Peking Union Medical College Hospital | RECRUITING |
253 publications have been identified in PubMed for inherited retinal dystrophy. Research spans Basic Science / Preclinical (30%), Case Report / Case Series (19%), and Epidemiology / Natural History (18%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 77 | 30% |
Patient case studies | 47 | 19% |
Disease patterns and progression | 46 | 18% |
Research summaries | 31 | 12% |
Testing and diagnosis research | 20 | 8% |
New treatment approaches | 20 | 8% |
Clinical study results | 9 | 4% |
Other research | 3 | 1% |
Amaral RAS (2026). [PMID: 41716464](https://pubmed.ncbi.nlm.nih.gov/41716464/). *Exp Biol Med (Maywood)*. [Epidemiology / Natural History]
Ahmed H (2026). [PMID: 35881734](https://pubmed.ncbi.nlm.nih.gov/35881734/). *Unknown Journal*. [Epidemiology / Natural History]
Chawla H (2026). [PMID: 33232049](https://pubmed.ncbi.nlm.nih.gov/33232049/). *Unknown Journal*. [Review / Meta-Analysis]
Gao A (2026). [PMID: 42150613](https://pubmed.ncbi.nlm.nih.gov/42150613/). *Can J Ophthalmol*. [Basic Science / Preclinical]
Pagán-Melvin C (2026). [PMID: 41841063](https://pubmed.ncbi.nlm.nih.gov/41841063/). *Cureus*. [Epidemiology / Natural History]
Barthelemy N (2026). [PMID: 42011331](https://pubmed.ncbi.nlm.nih.gov/42011331/). *Am J Ophthalmol Case Rep*. [Case Report / Case Series]
Tsuboi T (2026). [PMID: 41553438](https://pubmed.ncbi.nlm.nih.gov/41553438/). *Japanese journal of ophthalmology*. [Epidemiology / Natural History]
Boutaud L (2026). [PMID: 40841990](https://pubmed.ncbi.nlm.nih.gov/40841990/). *Clin Genet*. [Basic Science / Preclinical]
Takács Á (2026). [PMID: 41595520](https://pubmed.ncbi.nlm.nih.gov/41595520/). *Genes*. [Diagnostic / Biomarker]
Chokpanuwat T (2026). [PMID: 41880975](https://pubmed.ncbi.nlm.nih.gov/41880975/). *Stem Cell Res*. [Basic Science / Preclinical]
AI-curated news mentioning inherited retinal dystrophy
Updated Aug 15, 2026
A study published in PubMed highlights inherited retinal dystrophy in an 11-month-old infant with Yunis-Varon syndrome linked to a homozygous FIG4 mutation. This research contributes to understanding the genetic underpinnings of these rare conditions.